Direct Answer
Decapeptide-12 (trade name Lumixyl; INCI Decapeptide-12) is a synthetic decapeptide (sequence H-Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr-OH) identified by phage-display screening. Published studies report competitive inhibition of tyrosinase — the rate-limiting enzyme in melanin synthesis — and small clinical pilots in melasma, two of them manufacturer-affiliated.
Summary Table
Evidence Level
Low
Key Information
Classification
Key Takeaways
- Synthetic brightening decapeptide (INCI Decapeptide-12; trade name Lumixyl)
- Sequence H-Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr-OH; CAS 137665-91-9; PubChem CID 25087629
- Identified via phage-display screening (Stanford researchers)
- Published as a competitive tyrosinase inhibitor (in vitro IC50 ~40 µM vs ~680 µM hydroquinone)
- Small melasma pilots reported ~40–50% pigment reduction — two of three cited studies manufacturer-affiliated
- Evidence is real but limited (small pilots; partial COI); one more independent study concurs
Scientific Overview
What is Decapeptide-12 (Lumixyl)?
Decapeptide-12 (INCI Decapeptide-12; trade name Lumixyl, Envy Medical) is a synthetic 10-amino-acid peptide, sequence H-Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr-OH (CAS 137665-91-9; molecular formula C65H90N18O17; molecular weight 1395.55 g/mol; PubChem CID 25087629). It was identified through phage-display peptide screening by researchers at Stanford University.
In Plain English
Decapeptide-12, sold as Lumixyl, is a lab-made peptide studied as a skin-brightening ingredient. Published research reports that it blocks tyrosinase — an enzyme the skin uses to make pigment — and small clinical pilots reported reduced melasma pigmentation. Two of the three cited studies were run by researchers affiliated with the product's maker, and the trials were small, so the evidence is real but limited.
Scientific Details
Decapeptide-12 is a topically applied cosmetic peptide studied as a tyrosinase inhibitor for skin brightening. In an in vitro study (Abu Ubeid et al., J Invest Dermatol 2009, PMID 19440221) it competitively inhibited tyrosinase, with a reported mushroom-tyrosinase IC50 of approximately 40 µM versus ~680 µM for hydroquinone in the same assay (an ~17-fold lower IC50), and approximately 25–35% inhibition of human tyrosinase at 100 µM. A small split-face, double-blind, placebo-controlled melasma pilot (Hantash & Jimenez, J Drugs Dermatol 2009, PMID 19663110) reported roughly 40–50% reduction in pigmentation over about 12–16 weeks; that study was manufacturer-affiliated. A more independent open-label evaluation (Kassim et al., J Cosmet Laser Ther 2012, PMID 22401652) concurred on skin brightening. The clinical evidence base is small (pilot-scale) and partly manufacturer-affiliated and should be read cautiously.
How It Works
Published in vitro work reports that decapeptide-12 acts as a competitive inhibitor of tyrosinase, the rate-limiting enzyme converting tyrosine toward melanin. By reducing tyrosinase activity it is proposed to lower melanogenesis and lighten hyperpigmentation. Reported potency in a mushroom-tyrosinase assay (IC50 ~40 µM) was lower than hydroquinone (~680 µM) in that study; inhibition of human tyrosinase was more modest (~25–35% at 100 µM). These are findings from a small number of studies, two by manufacturer-affiliated authors, and should not be read as established clinical efficacy.
Mechanism of Action
Competitive tyrosinase inhibition
cell
In vitro studies (Abu Ubeid et al., 2009, PMID 19440221) report competitive inhibition of tyrosinase — the rate-limiting enzyme in melanin synthesis — with a mushroom-tyrosinase IC50 of ~40 µM vs ~680 µM for hydroquinone, and ~25–35% inhibition of human tyrosinase at 100 µM. Reducing tyrosinase activity is proposed to lower melanogenesis (brightening).
Evidence Level
Human Evidence
Two small clinical studies are cited. A split-face, double-blind, placebo-controlled melasma PILOT (Hantash & Jimenez, 2009, PMID 19663110) reported roughly 40–50% pigmentation reduction over ~12–16 weeks, but was manufacturer-affiliated (an author was an officer/stockholder of the maker). An independent open-label evaluation (Kassim et al., 2012, PMID 22401652) concurred on skin brightening. Both are small; no large, independent, controlled trials are cited.
Animal Evidence
No animal studies are cited for this entry.
Cell Evidence
An in vitro study (Abu Ubeid et al., 2009, PMID 19440221) reported competitive inhibition of mushroom and human tyrosinase (mushroom IC50 ~40 µM vs ~680 µM hydroquinone; ~25–35% human-tyrosinase inhibition at 100 µM).
Limitations
The clinical evidence is limited to small pilot-scale studies; two of the three cited works have manufacturer affiliation (B.M. Hantash / Envy Medical, maker of Lumixyl), and reported percentages come from small samples. One more independent open-label study concurs on brightening. Findings should be interpreted cautiously and not as established efficacy.
Frequently Asked Questions
What is Decapeptide-12?
Decapeptide-12 (trade name Lumixyl, INCI Decapeptide-12) is a synthetic 10-amino-acid peptide (H-Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr-OH) identified by phage-display screening. It is used in topical skin-brightening products and has been studied as a tyrosinase inhibitor.
How is Decapeptide-12 described to work?
Published in vitro studies report that it competitively inhibits tyrosinase, the rate-limiting enzyme in melanin production, which is proposed to reduce pigmentation and brighten skin. In a mushroom-tyrosinase assay its IC50 (~40 µM) was lower than hydroquinone's (~680 µM) in the same study; inhibition of human tyrosinase was more modest (~25–35% at 100 µM).
Is there independent clinical evidence for Decapeptide-12?
Yes, but it is limited. Small clinical pilots reported reduced melasma pigmentation (roughly 40–50% over 12–16 weeks), but two of the three cited studies were conducted by authors affiliated with the manufacturer (Envy Medical, maker of Lumixyl). One more independent open-label study (Kassim et al., 2012) concurred on skin brightening. The studies are small and partly manufacturer-affiliated, so the evidence is real but should be read cautiously.
References
- Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. Journal of Investigative Dermatology. (authors affiliated with Envy Medical, maker of Lumixyl)Cell / In Vitrodoi:10.1038/jid.2009.124 →
- A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. Journal of Drugs in Dermatology. (authors affiliated with Envy Medical, maker of Lumixyl — B.M. Hantash, officer/stockholder)Human StudyPMID: 19663110 →
- Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12. Journal of Cosmetic and Laser Therapy. (independent of the manufacturer)Human Studydoi:10.3109/14764172.2012.672745 →
Alternative Names
- Lumixyl
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature and, where noted, manufacturer/supplier materials. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Consult a licensed healthcare provider. This entry summarizes small, partly manufacturer-affiliated studies; it does not assert established clinical efficacy for Decapeptide-12 and is not a recommendation to use the ingredient.
This page summarizes published research and is for informational purposes only; it is not medical advice.